Online Pharmacy's TOP10 Blood Lipid-lowering Drug Products Released

According to the latest data from Minet.com, in 2021, the sales of terminal blood lipid regulator chemical drugs in China's online pharmacies will be close to 580 million yuan, a year-on-year increase of 70.86%. The sales of TOP10 products increased across the board, and the sales growth rate of ezetimibe tablets was as high as 148.85%; the combined market share of atorvastatin and rosuvastatin exceeded 70%.

With the aging of the population and the trend of younger patients, the prevalence of hypercholesterolemia has increased significantly, and the demand for hypolipidemic drugs will continue to expand. According to data from Minet.com, in 2021, the sales of terminal blood lipid regulator chemicals in online pharmacies in China will be close to 580 million yuan, a year-on-year increase of 70.86%.

In terms of sub-categories, the market share of HMG-CoA reductase inhibitors (statins) is as high as 83.37%. 2.52%.

Among the TOP10 products of blood lipid regulators, the two star drugs, atorvastatin calcium tablets and rosuvastatin calcium tablets, have a combined market share of over 70%; the sales growth rate of cholesterol absorption inhibitor ezetimibe tablets is as high as 148.85%, ranking No. 1 three. Except for pitavastatin calcium tablets, the sales growth rate of the other 9 products is over 50%.

Among the TOP10 brands, 6 domestic brands are on the list, including Atorvastatin Calcium Tablets from Lepu Pharmaceuticals, Jialin Pharmaceuticals, and Qilu Pharmaceuticals, Amlodipine Atorvastatin Calcium Tablets from Hanhui Pharmaceuticals, and Nanjing Chia Tai Tianqing’s Atorvastatin Calcium Tablets. Rosuvastatin calcium tablets, pitavastatin calcium tablets of China Resources Shuanghe.